磁共振波谱定量测量瘤周谷氨酸、N-乙酰天冬氨酸和乳酸浓度预测胶质母细胞瘤相关难治性癫痫
本研究纳入2017年4月至2021年7月在爱媛大学医院按同一方案治疗的40例原发性胶质母细胞瘤患者,其中23例接受磁共振波谱(MRS)定量检测瘤周谷氨酸、N-乙酰天冬氨酸、肌酸和乳酸浓度。结果显示,癫痫患者(B型或C型)的谷氨酸和N-乙酰天冬氨酸值显著高于无癫痫患者(A型)(p<0.05);C型(难治性癫痫)的乳酸浓度显著高于B型(p=0.001)。作者认为MRS测量这些代谢物可能预测难治性癫痫,并可能作为继续使用抗癫痫药物的指标。
要点
- 23例胶质母细胞瘤患者中11例确认有癫痫,包括B型4例和C型7例。
- 癫痫患者(B型或C型)的谷氨酸和N-乙酰天冬氨酸值显著高于无癫痫患者(A型)(p<0.05)。
- C型(难治性癫痫)的乳酸浓度显著高于B型(p=0.001)。
核心结论
- 胶质母细胞瘤患者瘤周细胞外谷氨酸、N-乙酰天冬氨酸和乳酸浓度在难治性癫痫患者中显著升高。
- MRS测量这些代谢物可能预测此类患者的难治性癫痫,并可能作为继续使用抗癫痫药物的指标。
研究设计与样本
- 2017年4月至2021年7月在爱媛大学医院按同一治疗方案治疗40例原发性胶质母细胞瘤患者,其中23例接受MRS检测。
- 通过LC-Model测定肿瘤周边谷氨酸、N-乙酰天冬氨酸、肌酸和乳酸浓度,各代谢物浓度以与肌酸浓度的比值表示。
- 患者分为三组:A型无癫痫;B型治疗后癫痫消失;C型癫痫未缓解或治疗后出现(难治性癫痫)。
主要发现
- 23例胶质母细胞瘤中11例确认有癫痫,包括B型4例和C型7例。
- 癫痫患者(B型或C型)的谷氨酸和N-乙酰天冬氨酸值显著高于无癫痫患者(A型)(p<0.05)。
- B型与C型之间谷氨酸或N-乙酰天冬氨酸水平无显著差异。
- C型乳酸浓度显著高于B型(p=0.001)。
- 难治性癫痫的乳酸/肌酸、谷氨酸/肌酸和N-乙酰天冬氨酸/肌酸比值截断值分别为>1.25、>1.09和>0.88。
关键数值与推荐
- 难治性癫痫的乳酸/肌酸比值截断值为>1.25。
- 难治性癫痫的谷氨酸/肌酸比值截断值为>1.09。
- 难治性癫痫的N-乙酰天冬氨酸/肌酸比值截断值为>0.88。
临床怎么用
- 作者认为MRS测量这些代谢物可能预测胶质母细胞瘤患者的难治性癫痫,并可能作为继续使用抗癫痫药物的指标。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Increased extracellular glutamate is known to cause epileptic seizures in patients with glioblastoma (GBM). However, predicting whether the seizure will be refractory is difficult. The present study investigated whether evaluation of the levels of various metabolites, including glutamate, can predict the occurrence of refractory seizure in GBM by quantitative measurement of metabolite concentrations on magnetic resonance spectroscopy (MRS). METHODS: Forty patients were treated according to the same treatment protocol for primary GBM at Ehime University Hospital between April 2017 and July 2021. Of these patients, 23 underwent MRS to determine concentrations of metabolites, including glutamate, N-acetylaspartate, creatine, and lactate, in the tumor periphery by applying LC-Model. The concentration of each metabolite was expressed as a ratio to creatine concentration. Patients were divided into three groups: Type A, patients with no seizures; Type B, patients with seizures that disappeared after treatment; and Type C, patients with seizures that remained unrelieved or appeared after treatment (refractory seizures). Relationships between concentrations of metabolites and seizure types were investigated. RESULTS: In 23 GBMs, seizures were confirmed in 11 patients, including Type B in four and Type C in seven. Patients with epilepsy (Type B or C) showed significantly higher glutamate and N-acetylaspartate values than did non-epilepsy patients (Type A) (p < 0.05). No significant differences in glutamate or N-acetylaspartate levels were seen between Types B and C. Conversely, Type C showed significantly higher concentrations of lactate than did Type B (p = 0.001). Cutoff values of lactate-to-creatine, glutamate-to-creatine, and N-acetylaspartate-to-creatine ratios for refractory seizure were > 1.25, > 1.09, and > 0.88, respectively. CONCLUSIONS: Extracellular concentrations of glutamate, N-acetylaspartate, and lactate in the tumor periphery were significantly elevated in patients with GBM with refractory seizures. Measurement of these metabolites on MRS may predict refractory epilepsy in such patients and could be an indicator for continuing the use of antiepileptic drugs.
引用
- Nakamura Y, Inoue A, Nishikawa M, et al. Quantitative measurement of peritumoral concentrations of glutamate, N-acetyl aspartate, and lactate on magnetic resonance spectroscopy predicts glioblastoma-related refractory epilepsy. Acta Neurochir (Wien). 2022. PMID: 36107232. doi:10.1007/s00701-022-05363-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。